Literature DB >> 3136081

Activation of human monocyte-derived macrophages cultured on Teflon: response to interferon-gamma during terminal maturation in vitro.

R Andreesen1, S Gadd, W Brugger, G W Löhr, R C Atkins.   

Abstract

Macrophages (M phi) are potential antitumor effector cells derived from circulating blood monocytes (mo). Most studies on human mo/M phi biology and function have been performed using immature mo precursor cells. However, the conclusions drawn may be questionable, as mo have to undergo terminal differentiation before they reach relevant tissue sites of inflammation and immune reaction. We have analyzed the ability of mo-derived, teflon-cultured M phi to respond to activating stimuli with an increased tumor cytotoxic effector cell function using recombinant interferon-gamma (IFN-gamma), IFN-alpha 2, granulocyte/macrophage colony stimulating factor (GM-CSF), interleukin(IL) 2, IL 1 alpha, and bacterial lipopolysaccharides (LPS) as mediator molecules. It could be shown that the response of M phi to the most potent activator molecule, IFN-gamma, depends on the terminal differentiation from the mo stage to the mature M phi. Whereas adherent mo could be activated only moderately, M phi increased their cytotoxicity by a factor of up to 400. IFN-gamma activation positively correlated with the effector cell number, the time of incubation and the dosage used. Activation did not depend on the presence of LPS, and was lost within 24 to 48 h. LPS itself activated cells only in the microgram range. IFN-alpha 2 activated M phi only at a two log higher concentration than IFN-gamma; GM-CSF was only slightly effective, whereas M phi incubation with IL 1 alpha or IL 2 did not result in M phi activation. Thus, the ability of human M phi to become activated appears to be a function of cellular maturation and is acquired during the terminal step of M phi differentiation. Teflon-cultured M phi could facilitate studies of the activation of human M phi and may be more suitable cells for adoptive immunotherapy in cancer patients than blood monocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3136081     DOI: 10.1016/s0171-2985(88)80038-x

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  6 in total

1.  Recombinant interferon gamma up-regulates in vivo and down-regulates in vitro monocyte CD14 antigen expression in cancer patients.

Authors:  R Landmann; M Wesp; C Ludwig; R Obrist; C Knüsli; J P Obrecht
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

2.  Therapeutical effect of activated human macrophages on a human tumor line growing in nude mice.

Authors:  S Ben-Efraim; C Tak; J C Romijn; M J Fieren; I L Bonta
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

3.  Aberrant expression of T cell and B cell markers in myelocyte/monocyte/histiocyte-derived lymphoma and leukemia cells. Is the infrequent expression of T/B cell markers sufficient to establish a lymphoid origin for Hodgkin's Reed-Sternberg cells?

Authors:  S M Hsu; P L Hsu
Journal:  Am J Pathol       Date:  1989-01       Impact factor: 4.307

4.  Elevated levels of soluble CD14 in serum of patients with systemic lupus erythematosus.

Authors:  W A Nockher; R Wigand; W Schoeppe; J E Scherberich
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

5.  Adsorbed serum albumin is permissive to macrophage attachment to perfluorocarbon polymer surfaces in culture.

Authors:  M L Godek; R Michel; L M Chamberlain; D G Castner; D W Grainger
Journal:  J Biomed Mater Res A       Date:  2009-02       Impact factor: 4.396

Review 6.  Chemopreventive Effects of Phytochemicals and Medicines on M1/M2 Polarized Macrophage Role in Inflammation-Related Diseases.

Authors:  Yen-Chun Koh; Guliang Yang; Ching-Shu Lai; Monthana Weerawatanakorn; Min-Hsiung Pan
Journal:  Int J Mol Sci       Date:  2018-07-28       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.